Agonist-Antagonist Opioids: Theory and Clinical Practice Carl Rosow MD

Total Page:16

File Type:pdf, Size:1020Kb

Agonist-Antagonist Opioids: Theory and Clinical Practice Carl Rosow MD REFRESHER COURSE OUTLINE $5 Agonist-antagonist opioids: theory and clinical practice Carl Rosow MD This presentation will deal with the heterogeneous group The diversion and abuse of fentanyl by anaesthetic of opioid analgesics possessing opioid antagonist proper- personnel was not widely appreciated until recently. ties. The clinically available drugs of this class are pentazocine, butorphanol, nalbuphine, buprenorphine, Mechanism of action and meptazinol (in the UK). At this writing, dezocine has When an opioid binds to its receptor it may produce a completed human trials and awaits FDA approval in the variable degree of effect: A full agonist like fentanyl or US. morphine can produce intense analgesia and respiratory The prototype agonist-antagonist, N-allylnormorphine depression, while a competitive antagonist like naloxone (nalorphine), was tested in animals and shown to be a binds with high affinity but produces little or no effect. morphine antagonist as early as 1930. Nalorphine was Nalorphine and all of the other agonist-antagonists thought to be devoid of analgesic effects until the early behave as partial agonists; these drugs tend to have 1950's when Lasagna and Beecher discovered that it had shallow dose-response curves and produce lower maxi- analgesic potency comparable to morphine. ~ They noted mal effects. Although this means that there is a "ceiling" that it produced typical morphine-like effects such as to the analgesic effects, toxic effects are limited as well. miosis and respiratory depression, but it also produced Keats and Telford showed, for example, that increasing unexpected effects like dysphoria and hallucinations. doses of nalorphine produced very limited increases in At nearly the same time Wikler and others showed that respiratory depression. 3 nalorphine could precipitate a violent withdrawal syn- Martin and his coworkers have postulated that the drome in opioid-dependent individuals. 2 When it was opioid alkaloids interact with (at least) three different given to former heroin addicts they experienced no receptors called mu, kappa, and sigma (Table I). 4 Each euphoria or drug craving. opioid may act as an agonist, a partial agonist or an The dysphoric effects and hallucinations made nalor- antagonist at each receptor (Table II). Nalorphine, pen- phine unacceptable as an analgesic (although it was used tazocine, butorphanol, and nalbuphine are thought to for years as an antagonist). It is much more significant that produce their analgesic and sedative effects by interacting nalorphine was the first potent analgesic which had little with kappa receptors. Each of them has affinity, but no or no addictive liability. The pharmaceutical industry was efficacy, at mu receptors and therefore acts as a morphine motivated to synthesize and test thousands of nalorphine antagonist. Dysphoria and hallucinations are thought to congeners, and a few of these have proved to be useful be mediated by sigma receptors. analgesics with a very low potential for abuse. Buprenorphine, dezocine, and meptazinol also have Thus far, the agonist-antagonist analgesics have not agonist and antagonist effects, but they are thought to be attained widespread popularity in anaesthetic practice. I partial agonists at mu receptors. Buprenorphine has been attribute this to three factors: shown to have extremely high affinity and relatively low I Much of the research done on these agents is not efficacy at mu receptors. When given alone, it produces directly applicable to the anaesthetic setting. effects which appear similar to morphine. When given 2 There is still widespread misunderstanding of agonist- after morphine, it displaces the full agonist and causes a antagonist pharmacology. These drugs were initially reduction in opioid effect. marketed as less abusable substitutes for morphine and As you might imagine, reversal of morphine with a mu fentanyl. Many anaesthetists were surprised to discover or kappa partial agonist is not as straightforward as that they differed from the pure agonists in some reversal with naloxone. In the presence of a fixed amount important ways. For some perioperative uses of mor- of morphine a small dose of nalorphine may antagonize phine or fentanyl the agonist-antagonist analgesics were probably not satisfactory substitutes. 3 The advantage of low-abuse potential i8 (unfortunately) Massachusetts General Hospital, Anaesthesia Dept., Fruit not generally perceived to be relevant to our specialty. Street, Boston, MA 02114, (617) 726-8812. CAN I ANAESTH 1989 / 36:3 t ppS$-SS S6 CANADIAN JOURNAL OF ANAESTHESIA TABLE l Opioidreceptor subtypesadapted from Martin(Ref. 4) agonist properties are more evident. Given alone, even extremely large doses of these drugs will usually not Receptor produce a state of "anaesthesia" as might be seen with Response mu kappa sigma fentany] or its derivatives.7 Compared with fentanyl, the agonist-antagonists produce more limited decreases in analgesia yes yes no respiratorydepression yes yes no requirements for potent volatile anaesthetics, s bchaviour euphoria sedation dysphoria pupil constriction yes yes no Sedation and mood effects morphine aubsitution yes no no A morphine-like agonist produces pain relief which is usually accompanied by dissociation, drowsiness, and mood elevation. As the dose is raised there is progressive- Table II Receptorinteractions* for variousopioids ly more mental clouding, lethargy, and stupor. Patients Receptor given the kappa-type agonist-antagonist pentazocine may experience floating and dissociation, but usually not Dr~ mu kappa s~ma mood elevation.9 They often appear extremely sedated Fentanyl Ag - yet remain capable of suprisingly lucid conversation. Morphine Ag Ag Sometimes the sedation will appear greater than the self-described relief of pain. With higher doses pat[ants Nalorphine Antag P Ag Ag are much more likely to experience "weird" feelings, Pentazocian Antag P Ag Ag Butorphanol Antag P Ag P Ag depersonalization, or hallucinations. The dysphoric ef- Nalbuphioe Antag P Ag P Ag fects are much more prominent with pentazocine than with butorphanol or nalbuphine. The subjective effects of Buprenorphine P Ag - the mu partial agonists (buprenorphine and dezocine) are Dezecine P Ag - morphine-like throughout the dose range. Meptaninol P Agl" - These mood effects have important therapeutic impli- *Ag = Agonist;P Ag ~ PartialAgonist; Antag = Antagonist. cations. Most physicians are very familiar with the 1"Othermechanisms probably play a role in the analgesiceffect. pleasant mental detachment produced by morphine and use it as a sign of drug effect. Since euphoria does not the opiate effects, while a large dose may actually usually occur with the agonist-antagonists there is a increase them. The net effect therefore depends upon the tendency to ascribe lack of mood elevation to lack of ratio of morphine to nalorphine. 5 analgesia. Kaiko et al. showed that these two effects are These drugs vary widely in antagonist and agonist separable in a multi-dose comparison of meptazinol and potency. Neither agonist vs. antagonist potency nor morphine in postoperafve pain. io Using a standard postop- hypothetical receptor interaction has proved to be a good erative pain model they showed that both drugs produced predictor of clinical utility or patient acceptance. dose-related pain relief, but only morphine produced dose-related improvement in mood. It is important to Clinical pharmacology remember that abuse of morphine is largely attributable to its euphoriant effects. While we want these drugs to make Analgesia our patients feel better, it is not clear whether mood The clinically available agonist-antagonists possess suf- elevation is always necessary or desirable in an analgesic. ficient analgesic activity to be effective in a variety of The prominent sedative effects of butorphanol or acute and chronic pain states. They have been shown to be nalbuphine may be advantageous in some clinical situa- sufficient for treatment of postoperative pain, trauma, tions. Butorphanol has shown promise as a sedative either bums, labour pain, renal colic, etc. They have been given alone or in combination with a benzodiazepine, i] In my intramuscularly, orally, sublingually, intranasally, intra- own practice, small doses (1-4 mg) of butorphanol, with venously by bolus or continuous infusion, and in patient- or without midazolam, are useful adjuncts to regional controlled analgesia systems. Several have been used anaesthetic techniques. The lower end of this dose range successfully by the epidural route. The initial reports on is suitable for elderly patients and those scheduled for epidural butorphanol after Caesarean section seem prom- discharge the same day. ising: Abboud reported that it produces excellent pain relief and little or no pruritus. 6 Respiratory depression Agonist-antagonists can be used successfully as part of Much has been made of the limited respiratory depression a balanced anaesthetic technique, but here their partial exhibited by these drugs. Respiratory depression after 2 or Rosow: AGONIST-ANTAGONIST OPIOIDS: THEORY AND CLINICAL PRACTICE $7 4 mg of butorphanol is equivalent to that produced by 10 much weaker as an antagonist, since it produces only mild mg of morphine, t2 Respiratory depression reaches a abstinence in addicts maintained on 30 mg methadone per maximum after about 30 mg of nalbuphine. ,3 Even larger day. 21 Even appropriate long-term use of opiates can doses are well tolerated by most patients, but severe gradually produce
Recommended publications
  • 2.0 Synopsis
    Hydrocodone/Acetaminophen Extended Release Tablets M12-807 Abbreviated Clinical Study Report R&D/11/661 2.0 Synopsis Abbott Laboratories Individual Study Table Referring (For National Authority to Part of Dossier: Use Only) Name of Study Drug: Volume: Hydrocodone/Acetaminophen Extended Release Page: Name of Active Ingredient: Hydrocodone 10 mg/ Acetaminophen 650 mg Extended Release Title of Study: A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects with Chronic Low Back Pain Coordinating Investigator: Study Sites: Seventeen investigative sites in the United States Publications: None Studied Period (Years): Phase of Development: 2 First Subject First Visit: 22 June 2011 Last Subject Last Visit: 28 October 2011 Objectives: The primary objective of this study was to compare the analgesic efficacy and safety of 1 tablet of hydrocodone/acetaminophen extended release 10 mg/650 mg administered twice daily over 2 weeks to placebo in subjects with moderate to moderately severe chronic low back pain (CLBP). A secondary objective of this study was to explore the population pharmacokinetics of hydrocodone and acetaminophen resulting from administration of hydrocodone/acetaminophen extended release 10 mg/650 mg tablets. Methodology: This Phase 2, multicenter, double-blind (DB), placebo-controlled, randomized withdrawal study compared the analgesic efficacy and safety of 1 tablet hydrocodone/acetaminophen extended release 10 mg/650 mg to placebo in subjects with moderate to moderately severe CLBP. Subjects met pre-defined criteria at the conclusion of the Open-Label (OL) Titration Period to proceed to randomization into the DB Maintenance Period of the study.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • (Butorphanol Tartrate) Nasal Spray
    NDA 19-890/S-017 Page 3 ® STADOL (butorphanol tartrate) Injection, USP STADOL NS® (butorphanol tartrate) Nasal Spray DESCRIPTION Butorphanol tartrate is a synthetically derived opioid agonist-antagonist analgesic of the phenanthrene series. The chemical name is (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol [S- (R*,R*)] - 2,3 - dihydroxybutanedioate (1:1) (salt). The molecular formula is C21H29NO2,C4H6O6, which corresponds to a molecular weight of 477.55 and the following structural formula: Butorphanol tartrate is a white crystalline substance. The dose is expressed as the tartrate salt. One milligram of the salt is equivalent to 0.68 mg of the free base. The n-octanol/aqueous buffer partition coefficient of butorphanol is 180:1 at pH 7.5. STADOL (butorphanol tartrate) Injection, USP, is a sterile, parenteral, aqueous solution of butorphanol tartrate for intravenous or intramuscular administration. In addition to 1 or 2 mg of butorphanol tartrate, each mL of solution contains 3.3 mg of citric acid, 6.4 mg sodium citrate, and 6.4 mg sodium chloride, and 0.1 mg benzethonium chloride (in multiple dose vial only) as a preservative. NDA 19-890/S-017 Page 4 STADOL NS (butorphanol tartrate) Nasal Spray is an aqueous solution of butorphanol tartrate for administration as a metered spray to the nasal mucosa. Each bottle of STADOL NS contains 2.5 mL of a 10 mg/mL solution of butorphanol tartrate with sodium chloride, citric acid, and benzethonium chloride in purified water with sodium hydroxide and/or hydrochloric acid added to adjust the pH to 5.0. The pump reservoir must be fully primed (see PATIENT INSTRUCTIONS) prior to initial use.
    [Show full text]
  • The Cardiovascular Actions of Mu and Kappa Opioid Agonists In
    THE CARDIOVASCULAR ACTIONS OF MU AND KAPPA OPIOID AGONISTS IN VIVO AND IN VITRO. By Abimbola T. Omoniyi, BSc (Hons) A thesis submitted in accordance with the requirements of the University of Surrey for the Degree of Doctor of Philosophy. Department of Pharmacology, September 1998. Cornell University Medical College, New York, NY 10021, ProQuest Number: 27733163 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 27733163 Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106 - 1346 ACKNOWLEDGEMENTS I would like to thank God through whom all things are made possible. Many thanks to Dr. Hazel Szeto for funding this thesis. Heartfelt gratitude to Dr. Dunli Wu for his support, encouragement and for keeping me sane. I thoroughly enjoyed the funny stories, the relentless Viagra jokes and endless tales of the Chinese revolution! Thanks to Dr. Yi Soong for all her support and generous assistance and all that food! Thanks to Dr. Ian Kitchen and Dr. Susanna Hourani for making this a successful collaborative degree. Thanks to my family for all their support and belief in me.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Ketamine Homogeneous Enzyme Immunoassay (HEIA™)
    Ketamine Homogeneous Enzyme Immunoassay (HEIA™) Exclusively from Immunalysis Formula: C13H16CINO Semi-Quantitative or Qualitative Testing Systematic Name: (RS)- 2- (2- chlorophenyl)- 2- (methylamino)cyclohexanone Accurate and reliable Brand Names: Ketanest®, Ketaset®, Ketalar® Ready to use About Ketamine: Ketamine is an anesthetic agent used in the United States since 1972 for veterinary and pediatric medicine. It is also used in the treatment of depression and postoperative pain management. However, in recent years it has gained popularity as a street drug used at clubs and raves due to its hallucinogenic effects. Administration: Oral; intravenous; intramuscular; insufflation Elimination: Ketamine metabolizes by N-demethylation to Norketamine and further dehydrogenates to Dehydronorketamine. After 72 hours of a single dose, 2.3% of Ketamine is unchanged, 1.6% is Norketamine, 16.2% is Dehydronorketamine, and 80% is hydroxylated derivatives of Ketamine.1,2 Abuse Potential: An overdose can cause unconsciousness and dangerously slowed breathing. 1) R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, Fourth Edition, p. 412-414. 2) K. Moore, J.Skerov, B.Levine, and A.Jacobs, Urine Concentrations of Ketamine and Norketamine Following Illegal Consumption, J.Anal, Toxicol. 25: 583-588 (2001). Ketanest® is a registered trademark of Pfizer, Inc., Ketaset® is a trademark of ZOETIS W LLC., Ketalar® is a trademark of PAR STERILE PRODUCTS, LLC. Tel 909.482.0840 | Toll Free 888.664.8378 | Fax 909.482.0850 ISO13485:2003 www.immunalysis.com CERTIFIED
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Nubain Product Monograph.Pdf
    PRODUCT MONOGRAPH ©NUBAIN (Nalbuphine Hydrochloride) Injection, 10 mg/mL Opioid Analgesic Adjunct Anesthetic Sandoz Canada Inc. 145 Jules-Léger Boucherville, Quebec, J4B 7K8 Date of Revision: April 03, 2018 Submission Control No: 213120 Nubain Page 1 of 34 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ............................................. 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................. 12 DRUG INTERACTIONS ............................................................................................. 14 DOSAGE AND ADMINISTRATION ......................................................................... 15 OVERDOSAGE ........................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ....................................................... 19 STORAGE AND STABILITY ..................................................................................... 20 SPECIAL HANDLING INSTRUCTIONS .................................................................. 20 DOSAGE FORMS, COMPOSITION
    [Show full text]
  • Table 6.12 Deaths from Poisoning, by Sex and Cause, Scotland, 2004
    Table 6.12 Deaths from poisoning, by sex and cause, Scotland, 2004 ICD Cause of death Both Males Females ICD Cause of death Both Males Females Codes and substance sexes Codes and substance sexes ACCIDENTS INTENTIONAL SELF-HARM X40 Accidental poisoning by and exposure X60 Intentional self-poisoning by -49 to noxious substances 57 40 17 -69 and exposure to 166 92 74 X40 Nonopioid analgesics, antipyretics X60 Nonopioid analgesics, antipyretics and antirheumatics and antirheumatics Ibuprofen 1 1 - Meptazinol, Alcohol 1 1 - Paracetamol 1 - 1 Meptazinol, Dihydrocodeine, Amitriptyline, Tramadol, Alcohol 1 1 - Imipramine, Alcohol 1 1 - Paracetamol 15 6 9 X41 Antiepileptic, sedative-hypnotic, Paracetamol, Codeine, Alcohol 1 1 - antiparkinsonism and Paracetamol, Diazepam 1 - 1 psychotropic drugs, Paracetamol, Oxazepam 1 1 - not elsewhere classified Tramadol 3 - 3 Clozapine, Diazepam, Alcohol 1 - 1 X61 Antiepileptic, sedative-hypnotic, antiparkinsonism and X42 Narcotics and psychodysleptics psychotropic drugs, (hallucinogens), not elsewhere not elsewhere classified classified Amitriptyline 8 3 5 Cocaine, Amphetamine 1 - 1 Amitriptyline, Alcohol 1 1 - Codeine, Tylex, Paracetamol, Alcohol 1 - 1 Amitriptyline, Dihydrocodeine 1 - 1 Dihydrocodeine, Diazepam 1 - 1 Amitriptyline, Paracetamol 1 1 - Ecstasy 1 1 - Carbamazepine 2 - 2 Heroin 4 3 1 Carbamazepine, Paroxetine, Paracetamol 1 1 - Heroin, Cocaine 1 1 - Chlordiazepoxide, Co-proxamol 1 - 1 Heroin, Methadone, Alcohol 1 1 - Chlorpromazine, Alcohol 2 2 - Heroin, Morphine 1 1 - Citalopram, Alcohol 1 -
    [Show full text]